RGT-61159, an RNA-targeting small molecule with efficacy in cancer models driven by MYB dysregulation June 14, 2024 ...
WOBURN, Mass., April 25, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback